Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Locally advanced breast cancer.

W M Sikov1

  • 1Department of Medicine, Room 320, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Multimodal therapy significantly improves outcomes for locally advanced breast cancer (LABC). Neoadjuvant chemotherapy and surgical approaches enhance survival, but pathologic complete response remains low.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okines and N. Turner.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.

Breast cancer research and treatment·2021
Same author

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016
Same author

Web alert.

Current oncology reports·2001
Same author

Splenosis presenting as occult gastrointestinal bleeding.

American journal of hematology·2000

Area of Science:

  • Oncology
  • Breast Cancer Research
  • Clinical Therapeutics

Background:

  • Locally advanced breast cancer (LABC) prognosis has improved with multimodal therapy over 20 years.
  • Neoadjuvant chemotherapy (NAC) enables breast-conserving surgery (BCS) and resections in inoperable LABC.
  • Pathologic complete response (CR) rates with NAC are low, and survival correlates with residual disease.

Purpose of the Study:

  • To review current multimodal treatment strategies for LABC.
  • To evaluate the impact of chemotherapy regimens, surgical techniques, and adjuvant therapies on LABC outcomes.
  • To identify areas for improvement in LABC management.

Main Methods:

  • Review of anthracycline-based NAC regimens and taxane additions.
  • Analysis of surgical approaches including BCS, partial mastectomy, and lymph node dissection (SLN sampling).
  • Evaluation of adjuvant therapies (chemotherapy, hormonal therapy, radiation) and their impact on disease-free survival (DFS) and overall survival (OS).

Main Results:

  • Taxane-containing regimens increase response rates and may improve DFS.
  • BCS is oncologically safe for most LABC patients, with modified nodal dissection reducing morbidity.
  • Adjuvant tamoxifen improves outcomes in hormone receptor-positive (HR+) tumors; ovarian ablation is considered for premenopausal patients.
  • Postoperative radiation reduces locoregional recurrences, but OS impact is debated.
  • Neoadjuvant hormonal therapy may benefit frail patients with HR+ tumors.

Conclusions:

  • Multimodal therapy, including NAC with taxanes and appropriate surgical techniques, has significantly improved LABC outcomes.
  • Adjuvant hormonal therapy is crucial for HR+ LABC. Further research is needed on radiation's OS impact.
  • Current targeted therapies like trastuzumab lack a proven role in LABC management.

Related Experiment Videos